×
Baxter Cash on Hand 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter cash on hand for the quarter ending December 31, 2024 was
$1.764B
, a
42.69% decline
year-over-year.
Baxter cash on hand for 2024 was
$1.764B
, a
42.69% decline
from 2023.
Baxter cash on hand for 2023 was
$3.078B
, a
79.16% increase
from 2022.
Baxter cash on hand for 2022 was
$1.718B
, a
41.78% decline
from 2021.
View More
Baxter Cash on Hand 2010-2024 | BAX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Baxter cash on hand for 2024 was
$1.764B
, a
42.69% decline
from 2023.
Baxter cash on hand for 2023 was
$3.078B
, a
79.16% increase
from 2022.
Baxter cash on hand for 2022 was
$1.718B
, a
41.78% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$229.2B
Boston Scientific (BSX)
$155.9B
Stryker (SYK)
$148.3B
EssilorLuxottica (ESLOY)
$140.1B
Medtronic (MDT)
$111.6B
Lonza Group Ag (LZAGY)
$46.2B
Haleon (HLN)
$45.2B
GE HealthCare Technologies (GEHC)
$42.3B
Agilent Technologies (A)
$39.1B
ResMed (RMD)
$34.4B
Terumo (TRUMY)
$26.6B
Koninklijke Philips (PHG)
$23.5B
Zimmer Biomet Holdings (ZBH)
$20.6B
Insulet (PODD)
$19.9B
Sunny Optical Technology (SNPTF)
$11.3B
Smith & Nephew SNATS (SNN)
$11.2B
BellRing Brands (BRBR)
$9.9B
Demant (WILYY)
$7.9B
Bio-Rad Laboratories (BIO)
$7.9B
Lantheus Holdings (LNTH)
$5.7B
Prestige Consumer Healthcare (PBH)
$4.2B
ICU Medical (ICUI)
$4B
Envista Holdings (NVST)
$3.7B
Perrigo (PRGO)
$3.4B
Haemonetics (HAE)
$3.2B
Shandong Weigao Medical Polymer (SHWGF)
$3B
GN Store Nord (GNNDY)
$2.9B
QuidelOrtho (QDEL)
$2.8B
LeMaitre Vascular (LMAT)
$2.3B
Neogen (NEOG)
$2.2B